Determinants of One-Year Success in Descemet Membrane Endothelial Keratoplasty: Insights from the Diabetes Endothelial Keratoplasty Study
Posted inDiabetes & Endocrinology news Ophthalmology

Determinants of One-Year Success in Descemet Membrane Endothelial Keratoplasty: Insights from the Diabetes Endothelial Keratoplasty Study

This article examines factors influencing the one-year success rate of DMEK in treating corneal endothelial dysfunction, highlighting the impact of operative complications and donor-recipient variables based on findings from the Diabetes Endothelial Keratoplasty Study (DEKS).
Ticagrelor Falls Short: TUXEDO-2 Trial Challenges Antiplatelet Choice in Diabetic Patients With Multivessel Disease
Posted inCardiology news

Ticagrelor Falls Short: TUXEDO-2 Trial Challenges Antiplatelet Choice in Diabetic Patients With Multivessel Disease

The TUXEDO-2 trial reveals that ticagrelor did not meet noninferiority criteria compared with prasugrel in diabetic patients with multivessel coronary artery disease undergoing PCI. At 1 year, the primary composite endpoint of death, MI, stroke, or major bleeding occurred in 16.6% vs 14.2% of patients, suggesting prasugrel may offer better outcomes in this high-risk population.
Semaglutide Shows Promise in Reducing Mental Illness Worsening in Patients with Depression and Anxiety, Swedish Study Finds
Posted inDiabetes & Endocrinology news Psychiatry

Semaglutide Shows Promise in Reducing Mental Illness Worsening in Patients with Depression and Anxiety, Swedish Study Finds

A landmark Swedish cohort study of 95,490 patients reveals that semaglutide is associated with a 42% lower risk of worsening mental illness in people with depression and anxiety, while other GLP-1 receptor agonists show varied effects. The findings suggest potential dual therapeutic benefits for metabolic and mental health conditions.